Boston Scientific Other accrued liabilities increased by 10.1% to $875.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 5.2%, from $923.00M to $875.00M. Over 5 years (FY 2020 to FY 2025), Other accrued liabilities shows a downward trend with a -3.7% CAGR.
Significant fluctuations may indicate changes in business model, such as shifts in deferred revenue recognition or changes in short-term regulatory obligations.
This category includes miscellaneous short-term obligations that are not classified under accounts payable or accrued li...
Commonly used as a catch-all for short-term liabilities; varies by industry and business model.
current_liabilities_other_liabilities_current| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $680.00M | $669.00M | $783.00M | $1.03B | $784.00M | $752.00M | $761.00M | $787.00M | $940.00M | $882.00M | $814.00M | $827.00M | $770.00M | $891.00M | $887.00M | $923.00M | $952.00M | $862.00M | $795.00M | $875.00M |
| QoQ Change | — | -1.6% | +17.0% | +32.1% | -24.2% | -4.1% | +1.2% | +3.4% | +19.4% | -6.2% | -7.7% | +1.6% | -6.9% | +15.7% | -0.4% | +4.1% | +3.1% | -9.5% | -7.8% | +10.1% |
| YoY Change | — | — | — | — | +15.3% | +12.4% | -2.8% | -23.9% | +19.9% | +17.3% | +7.0% | +5.1% | -18.1% | +1.0% | +9.0% | +11.6% | +23.6% | -3.3% | -10.4% | -5.2% |